PT854729E - Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente - Google Patents

Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente

Info

Publication number
PT854729E
PT854729E PT96932269T PT96932269T PT854729E PT 854729 E PT854729 E PT 854729E PT 96932269 T PT96932269 T PT 96932269T PT 96932269 T PT96932269 T PT 96932269T PT 854729 E PT854729 E PT 854729E
Authority
PT
Portugal
Prior art keywords
ultrafiltration
proteosomes
production
multivalent
proteosomeamphiphilic
Prior art date
Application number
PT96932269T
Other languages
English (en)
Inventor
George H Lowell
Wendell D Zollinger
James F Wood
Original Assignee
Us Army Med Res Mat Com Usamrm
Id Biomedical Corp Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21707938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT854729(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Army Med Res Mat Com Usamrm, Id Biomedical Corp Quebec filed Critical Us Army Med Res Mat Com Usamrm
Publication of PT854729E publication Critical patent/PT854729E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/008—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PT96932269T 1995-09-18 1996-09-18 Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente PT854729E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US385995P 1995-09-18 1995-09-18

Publications (1)

Publication Number Publication Date
PT854729E true PT854729E (pt) 2004-08-31

Family

ID=21707938

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96932269T PT854729E (pt) 1995-09-18 1996-09-18 Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente

Country Status (20)

Country Link
US (1) US6476201B1 (pt)
EP (1) EP0854729B2 (pt)
JP (2) JP4033489B2 (pt)
KR (1) KR19990045763A (pt)
CN (1) CN1211192A (pt)
AT (1) ATE261313T1 (pt)
BR (1) BR9610484A (pt)
CA (1) CA2232410C (pt)
CZ (1) CZ298460B6 (pt)
DE (1) DE69631835T3 (pt)
DK (1) DK0854729T3 (pt)
EA (1) EA199800208A1 (pt)
ES (1) ES2217325T5 (pt)
HU (1) HUP9901577A3 (pt)
IL (1) IL123720A (pt)
MX (1) MX9802128A (pt)
NO (1) NO320074B1 (pt)
PL (1) PL325604A1 (pt)
PT (1) PT854729E (pt)
WO (1) WO1997010844A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
ES2278446T3 (es) * 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
EP1179072A2 (en) 1999-05-19 2002-02-13 Chiron S.P.A. Combination neisserial compositions
EP1419784A3 (en) * 2000-02-15 2004-08-25 ID Biomedical Corporation of Quebec Proteosome vaccines against toxins, allergy and cancer
JP3980884B2 (ja) * 2000-02-15 2007-09-26 アイディー バイオメディカル コーポレイション オブ ケベック プロテオソーム・インフルエンザ・ワクチン
PT2270030E (pt) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
EP1372706B1 (en) * 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosome-liposaccharide vaccine adjuvant
CN1674933B (zh) * 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
EP2351579B1 (en) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
GB0316560D0 (en) * 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
JP2007505836A (ja) * 2003-09-15 2007-03-15 アイディー バイオメディカル コーポレイション オブ ケベック 麻疹サブユニットワクチン
JP4966661B2 (ja) 2003-10-22 2012-07-04 アイディー バイオメディカル コーポレイション オブ ケベック 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
NZ578727A (en) 2004-06-25 2011-03-31 Brigham & Womens Hospital Proteosome compositions and methods for treating neurological disorders
KR20070052273A (ko) * 2004-06-30 2007-05-21 아이디 바이오메디컬 코포레이션 오브 퀘벡 코로나바이러스 감염의 치료를 위한 백신 조성물
US7552948B2 (en) 2006-03-29 2009-06-30 Tokai Rubber Industries, Ltd. Quick connector
CN110064053A (zh) * 2006-08-07 2019-07-30 哈佛大学校长及研究员协会 蛋白质基质疫苗及这种疫苗的制备和给药方法
KR101446238B1 (ko) * 2006-08-07 2014-10-01 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 단백질 매트릭스 백신 및 그의 제조방법 및 백신 투여방법
JP2010502425A (ja) * 2006-08-30 2010-01-28 ジーイー・ヘルスケア・バイオサイエンス・コーポレイション 膜を評価するシステム及び方法並びに膜濾過装置
MX2010012999A (es) * 2008-05-30 2012-03-07 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
CA2773690A1 (en) * 2009-09-09 2011-03-17 Matrivax Research & Development Corp. Protein matrix vaccines of improved immunogenicity
EP4183408A1 (en) * 2014-09-24 2023-05-24 The United States of America as Represented by The Secretary of the Navy Combined enterotoxigenic escherichia coli and shigella recombinant
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
RU1522494C (ru) * 1987-06-16 1994-11-15 Научно-производственное объединение "Иммунопрепарат" Способ получения инактивированной вакцины гриппа
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
US5145702A (en) * 1988-09-19 1992-09-08 Opta Food Ingredients, Inc. Hydrophobic protein microparticles and preparation thereof
AU640118B2 (en) * 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
US5102989A (en) * 1991-03-15 1992-04-07 Merck & Co., Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells
AU4683093A (en) * 1992-07-20 1994-02-14 Merck & Co., Inc. Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
JP3980884B2 (ja) * 2000-02-15 2007-09-26 アイディー バイオメディカル コーポレイション オブ ケベック プロテオソーム・インフルエンザ・ワクチン

Also Published As

Publication number Publication date
NO320074B1 (no) 2005-10-17
EP0854729B2 (en) 2008-10-22
DE69631835T3 (de) 2009-03-05
DE69631835T2 (de) 2005-02-10
ATE261313T1 (de) 2004-03-15
JP4033489B2 (ja) 2008-01-16
HUP9901577A2 (hu) 1999-08-30
EP0854729A1 (en) 1998-07-29
MX9802128A (es) 1998-11-29
EP0854729B1 (en) 2004-03-10
EP0854729A4 (en) 2000-02-02
NO981189D0 (no) 1998-03-17
CZ298460B6 (cs) 2007-10-10
US6476201B1 (en) 2002-11-05
PL325604A1 (en) 1998-08-03
DE69631835D1 (de) 2004-04-15
ES2217325T5 (es) 2009-04-01
CZ81998A3 (cs) 1998-10-14
ES2217325T3 (es) 2004-11-01
DK0854729T3 (da) 2004-07-12
KR19990045763A (ko) 1999-06-25
CA2232410A1 (en) 1997-03-27
US20020164357A1 (en) 2002-11-07
JP2004099619A (ja) 2004-04-02
BR9610484A (pt) 2001-09-11
IL123720A0 (en) 1998-10-30
NO981189L (no) 1998-05-14
HUP9901577A3 (en) 2000-03-28
CA2232410C (en) 2003-06-17
WO1997010844A1 (en) 1997-03-27
CN1211192A (zh) 1999-03-17
IL123720A (en) 2002-02-10
EA199800208A1 (ru) 1998-10-29
JP2000507913A (ja) 2000-06-27

Similar Documents

Publication Publication Date Title
NO981189L (no) FremgangsmÕter for fremstilling av ikke-kovalent komplekserte og multivalente proteosom-subenhet-vaksiner
NO913518L (no) Vaksiner for ikke typebestembar haemophilus influenzae.
DE69423383D1 (de) Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
EP1297844A3 (en) Multicomponent meningococcal vaccine
DE69519664D1 (de) Verfahren zur herstellung fester pharmazeutischer dosierungsform
SE9003198D0 (sv) Fish vaccine comprising a virulent, invasive bacterium
ES2080210T3 (es) Metodo y sistema para la preparacion de una solucion medica, por ejemplo una solucion de dialisis.
ATE222930T1 (de) Antigene arznei zur behandlung oder vorbeugung
ES2108693T3 (es) Compuestos y tratamientos para la neumonia en animales.
ATE105189T1 (de) Haemophilus influenzae typ b polysaccharidaussermembranprotein-konjugat als impfstoff.
WO2023118457A1 (en) Method for preparing outer membrane vesicles
SE9601158D0 (sv) Method of producing immunogenic products and vaccines
EP0082072B1 (fr) Procédé de production d'un vaccin biochimique contre les fièvres à salmonelles
DE69329922D1 (de) Herstellung eines tetanusimpfstoffes
AU766772B2 (en) Immunogenic liposome compositions
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
IT1206250B (it) Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
Chaicumpa et al. Oral vaccine against cholera prepared from Vibrio cholerae antigen (s).
Homma et al. Effectiveness of immunization with multicomponent vaccines in protection against hemorrhagic pneumonia due to Pseudomonas aeruginosa infection in mink
RU96107607A (ru) Способ изготовления пуллорного эритроцитарного антигена для диагностики пуллороза - тифа птиц
RU93052669A (ru) Способ получения специфического лактоглобулина
Shewen et al. Process for the production of vaccine for prevention of Pasteurella haemolytica pneumonia in bovine
Ojo CHARACTERISTICS OF BORIC ACII) TOLERANT VIBRIO CHOLERAE
RU96123912A (ru) Способ иммунопрофилактики экспериментальной лепрозной инфекции
Asada et al. Arita, M. see Nomoto, A., 134 Arrhenius, T. see Satterthwait, AC, 99 Artamonov, AF see Berezin, VE, 450 Arya, SC Continuing global polio